Carlsmed Statistics
Total Valuation
Carlsmed has a market cap or net worth of $319.56 million. The enterprise value is $239.80 million.
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Carlsmed has 27.18 million shares outstanding. The number of shares has increased by 379.37% in one year.
| Current Share Class | 27.18M |
| Shares Outstanding | 27.18M |
| Shares Change (YoY) | +379.37% |
| Shares Change (QoQ) | +0.90% |
| Owned by Insiders (%) | 12.18% |
| Owned by Institutions (%) | 19.70% |
| Float | 9.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.66 |
| Forward PS | 3.91 |
| PB Ratio | 3.33 |
| P/TBV Ratio | 3.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.88, with a Debt / Equity ratio of 0.19.
| Current Ratio | 11.88 |
| Quick Ratio | 11.25 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.66 |
Financial Efficiency
Return on equity (ROE) is -52.43% and return on invested capital (ROIC) is -26.88%.
| Return on Equity (ROE) | -52.43% |
| Return on Assets (ROA) | -24.16% |
| Return on Invested Capital (ROIC) | -26.88% |
| Return on Capital Employed (ROCE) | -31.30% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $444,394 |
| Profits Per Employee | -$256,701 |
| Employee Count | 127 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 8.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.20 |
| 200-Day Moving Average | 12.42 |
| Relative Strength Index (RSI) | 63.37 |
| Average Volume (20 Days) | 164,756 |
Short Selling Information
The latest short interest is 671,550, so 2.47% of the outstanding shares have been sold short.
| Short Interest | 671,550 |
| Short Previous Month | 571,356 |
| Short % of Shares Out | 2.47% |
| Short % of Float | 6.78% |
| Short Ratio (days to cover) | 5.64 |
Income Statement
In the last 12 months, Carlsmed had revenue of $56.44 million and -$32.60 million in losses. Loss per share was -$1.64.
| Revenue | 56.44M |
| Gross Profit | 42.83M |
| Operating Income | -34.13M |
| Pretax Income | -32.60M |
| Net Income | -32.60M |
| EBITDA | -33.79M |
| EBIT | -34.13M |
| Loss Per Share | -$1.64 |
Full Income StatementBalance Sheet
The company has $97.02 million in cash and $17.26 million in debt, with a net cash position of $79.76 million or $2.93 per share.
| Cash & Cash Equivalents | 97.02M |
| Total Debt | 17.26M |
| Net Cash | 79.76M |
| Net Cash Per Share | $2.93 |
| Equity (Book Value) | 92.25M |
| Book Value Per Share | 3.39 |
| Working Capital | 105.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.83 million and capital expenditures -$638,000, giving a free cash flow of -$34.47 million.
| Operating Cash Flow | -33.83M |
| Capital Expenditures | -638,000 |
| Depreciation & Amortization | 340,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -34.47M |
| FCF Per Share | -$1.27 |
Full Cash Flow StatementMargins
Gross margin is 75.89%, with operating and profit margins of -60.48% and -57.76%.
| Gross Margin | 75.89% |
| Operating Margin | -60.48% |
| Pretax Margin | -57.76% |
| Profit Margin | -57.76% |
| EBITDA Margin | -59.87% |
| EBIT Margin | -60.48% |
| FCF Margin | n/a |
Dividends & Yields
Carlsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -379.37% |
| Shareholder Yield | -379.37% |
| Earnings Yield | -10.20% |
| FCF Yield | -10.79% |
Analyst Forecast
The average price target for Carlsmed is $18.40, which is 56.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.40 |
| Price Target Difference | 56.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Carlsmed has an Altman Z-Score of 7.11 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.11 |
| Piotroski F-Score | 3 |
